Annette Whittemore

Source:www.me-net.com

Annette Whittemore (not to be confused with Vicky Whittemore) is a patient advocate and the mother of a daughter, Andrea Whittemore-Goad, who has been sick with ME since she was a pre-teen. She was fundamental in establishing the research institute Whittemore Peterson Institute.

According to Ms. Whittemore's Linkedin page, her commitment to helping her daughter and others with similar illnesses is well documented:

• "1989 Began the search for knowledge and treatment for a young daughter's serious illness.
• 2001: Co-sponsored a CFS Think Tank for physicians and allied health professionals in Reno, Nevada.
• 2003: Supported amended Assembly Bill 502 in the Nevada State legislature requiring insurance companies in Nevada to provide coverage for medical treatment when part of a clinical trial in phase II, phase III, and phase IV, for patients with cancer and chronic fatigue syndrome (CFS), myalgic encephalomyelitis, ME/CFS.
• 2004: Co-founded the HHV-6 Foundation
• 2005: Successfully sought seed funding for a 70 million dollar joint medical research building project for the University of Nevada, Reno, Nevada Cancer Institute and the WPI
• 2006: Created the Neuro-Immune Research Foundation which became the foundation of support for WPI
• 2007: Successfully sought additional funding for building and operations for the Whittemore Peterson Institute."

Dr. Daniel Peterson left the Whittemore Peterson Institute in 2010 and returned to private practice.

By 2012, the Whittemore Peterson Institute had become embroiled in controversies, including its research into XMRV.

In 2016, the Whittemore Peterson Institute changed its name to the Nevada Center for Biomedical Research.

In January 2019, due to restructuring of the research program, the center returned to its original name, the Whittemore Peterson Institute.

Awards

• 2006, Health Care Hero Award, Nevada Business Journal
• 2008, University of Nevada, Alumna of the Year
• 2009, IACFS/ME Special Service Award - for outstanding personal effort and contribution to the CFS/ME community
• 2009, Honorary Doctor of Letters, University of Nevada, Reno

Talks and interviews

• 2007, Speaker at the 2nd Invest in ME International ME Conference - Speech title: A Model ME/CFS Clinic - The CFS Clinic – Reno, Nevada, US - (Video)

• 2009, Keynote Speaker at the 4th Invest in ME International ME Conference

• 2009 Conference DVD

• 2010, Speaker at the 5th Invest in ME International ME Conference - Speech title: Future Pathways of Research into ME

• 2010 Conference DVD

• 2011, Keynote Speaker at the 6th Invest in ME International ME Conference - Speech Title: Translating ME/CFS Research into Treatments

• 2011 Conference DVD

• 2011, 10th International IACFSME Conference, Patient Agenda - Speech title: "Translating Scientific Research into Patient Care"
• 2011, ME/CFS Alert - Episode 04 - Annette Whittemore, President of the Whittemore Peterson Institute

See also

• Nevada Center for Biomedical Research
• Judy Mikovits
• Daniel Peterson

phase two A trial involve patients to assess side effects and effectiveness for a particular clinical condition. Typically 100-300 patients.

phase three Last phase of clinical trials before a drug can be approved for public use. Whereas Phase one assesses basic safety, and Phase two assesses basic efficacy, Phase three uses many trial participants to fully assess both safety and efficacy, and overall benefit/risk.